At what enterprise value was X-RAY PHOCEA acquired in 2023?

You can find the full valuation details of X-RAY PHOCEA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of X-RAY PHOCEA when it was acquired by ESSLING CAPITAL?

The exact EV/EBITDA multiple for X-RAY PHOCEA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was X-RAY PHOCEA acquired by ESSLING CAPITAL?

X-RAY PHOCEA was acquired by ESSLING CAPITAL in 2023.

What was the revenue of X-RAY PHOCEA at the time of the deal?

The revenue of X-RAY PHOCEA at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the X-RAY PHOCEA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the X-RAY PHOCEA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cic-conseil.eu/fr/telechargements/x-ray-phocea.pdf

← DATABASE

Home Database Healthcare & PharmaX-RAY PHOCEA

12/2023

X-RAY PHOCEA acquired by ESSLING CAPITAL

FRANCE Health Providers / Outpatient Care / Radiology REV 5M - 25M EUR

Context

X-Ray Phocea, a leading medical imaging group in Southern France, has secured a strategic minority investment from Essling Expansion, alongside Bpifrance and SOFIPACA. Despite this new capital entry, the majority of the group�s shareholding remains in the hands of its 20 associate radiologists, preserving a practitioner-led management model.

X-RAY PHOCEA, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Network of medical imaging centers in the Marseille region.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2026

2025

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2024	INTEGRAL DIAGNOSTICS LIMITED	CAPITOL HEALTH LIMITED	AUSTRALIA	Radiology
01/2024	ARDIAN / BPIFRANCE / MACSF	APRIUM PHARMACIE	FRANCE	Pharmacy
12/2023	ANDERA PARTNERS	GROUPE IMAGERIE CARDINET	FRANCE	Radiology
10/2023	EQT PARTNERS	VETPARTNERS	AUSTRALIA	Vet Clinics
08/2023	BAIN CAPITAL	ESTIA HEALTH	AUSTRALIA	Nursing Homes
08/2023	QUADRIVIO GROUP	THE PRIVATE CLINIC (TPC)	UNITED KINGDOM	Aesthetic & Cosmetic Clinics
07/2023	MEDIAN KLINIKEN	HESTIA ALLIANCE	SPAIN	Clinics / Hospitals
06/2023	PARQUEST CAPITAL	IMANEO	FRANCE	Radiology
06/2023	ARDIAN	MON VETO	FRANCE	Vet Clinics
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Radiology

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of X-RAY PHOCEA by ESSLING CAPITAL are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: essling capital